Medicenna Therapeutics Corp. (TSX: MDNA, OTCQB: MDNAF) announced the results of its annual general and special meeting held on October 1, 2026, at which shareholders approved all resolutions put forward by management. Notably, shareholders authorised a potential share consolidation at a ratio ranging from one post-consolidation share for every 2 to 20 pre-consolidation shares, with the final ratio to be set by the board. The move signals Medicenna's stated interest in evaluating a potential listing on a major U.S. stock exchange, making the vote a development investors in this clinical-stage immunotherapy company will be watching closely.

Key Points

  • Medicenna Therapeutics Corp. (TSX: MDNA, OTCQB: MDNAF) held its annual general and special meeting on October 1, 2026.
  • Shareholders approved a share consolidation authorisation at a ratio of 1-for-2 to 1-for-20, subject to board discretion.
  • All four director nominees were elected with more than 97% of votes cast; MNP LLP was re-appointed as auditor.
  • Investors should watch for a board announcement confirming whether, and at what ratio, the consolidation will proceed.

Full Board Re-Elected with Strong Shareholder Support

All four nominees listed in Medicenna's management information circular dated August 19, 2026, were elected as directors. Albert Beraldo received 97.42% of votes cast in favour, Richard Sutin received 97.52%, Angelos Georgakis received 97.51%, and Dr. Fahar Merchant received 97.29%. Shareholders also approved the re-appointment of MNP LLP as the Company's auditor. A total of 31.82% of issued and outstanding common shares were represented in person or by proxy at the meeting, the Company disclosed.

Share Consolidation Authority Granted to Support Potential U.S. Exchange Listing

The special resolution approving the share consolidation authorises the board to set a ratio within the 1-for-2 to 1-for-20 range, while retaining discretion not to proceed at all. The Company states the consolidation may be undertaken as part of its evaluation of strategic opportunities, including supporting compliance with the minimum bid price requirements of a major U.S. stock exchange. Medicenna cautions that a consolidation would not guarantee satisfaction of all U.S. listing requirements, and any such listing remains subject to exchange approval and meeting all applicable conditions.

Medicenna's Clinical Pipeline Context for Investors

Medicenna is a clinical-stage immunotherapy company advancing engineered cytokine therapies. Its most advanced candidate, bizaxofusp, is a targeted IL-4 Empowered Superkine evaluated in more than 130 patients across five clinical trials, including a Phase 2b study in recurrent glioblastoma, and carries FDA Fast Track and Orphan Drug designations in both the United States and Europe. The company is also advancing MDNA11 in the Phase 1/2 ABILITY-1 and Phase 1b NEO-CYT studies, alongside earlier-stage programmes MDNA113 and MDNA209.